Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 52OTHER 36NIH 3NETWORK 3UNKNOWN 2OTHER_GOV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 3Recurrence 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

enzalutamide 3apalutamide 2relugolix 1pembrolizumab 1nilutamide 1histrelin 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Triptorelin Pamoate 1Prednisone 1Oxaliplatin 1Methylprednisolone 1Leuprolide 1Goserelin 1Flutamide 1Fecal Microbiota Transplantation 1Docetaxel 1Androgen Antagonists 1Abiraterone Acetate 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Neoplasm Metastasis × Docetaxel × Clear all
NCT00557206 2013-11-05

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

Minneapolis Veterans Affairs Medical Center

Phase 2 Terminated
35 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡